GPT and alopecia: With regard to individual AEs, some AEs occurred at a significantly higher incidence with vemurafenib plus cobimetinib compared with dabrafenib plus trametinib, including (in alphabetical order) alopecia, arthralgia, blurred vision, increased blood creatinine, diarrhea, dry skin, dysgeusia, increased alanine transaminase (ALT) and aspartate transaminase (AST), keratosis pliaris, nausea, photosensitivity reaction, pruritus, rash, rash maculopapular, skin papilloma, and sun burn (Table 5).